 biomarkers are being developed to predict a patient's response to cancer immunotherapy, allowing for individualized treatment tailoring. Immunotherapy inactivates immune checkpoints to restore the immune response against tumours, but has low response rates and can trigger severe autoimmune reactions. IODL Corda Catar Biomedical Research Institute reviewed biomarkers that could predict individual effects of immunotherapy, including markers based on immune response level and tumour genetics. Further research and testing are needed to improve the efficacy of this promising new cancer therapy. This article was offered by Promote Darwin, Salman M. Tua, foreign secedar and others.